key: cord-0912667-w05d8wa7
authors: Tsuchiya, Kazuo; Fujisawa, Tomoyuki; Mochizuka, Yasutaka; Takuma, Sho; Oishi, Kyohei; Endo, Yoshinari; Tanaka, Yuko; Fukada, Atsuki; Watanabe, Hirofumi; Katsumata, Mineo; Aoshima, Yoichiro; Inoue, Yusuke; Suzuki, Yuzo; Karayama, Masato; Hozumi, Hironao; Furuhashi, Kazuki; Enomoto, Noriyuki; Nakamura, Yutaro; Inui, Naoki; Suda, Takafumi
title: Transient leukocytopenia following combination therapy for COVID-19
date: 2021-10-09
journal: Respir Investig
DOI: 10.1016/j.resinv.2021.09.007
sha: 943e6ae2fe86004618f46aa617f09f5d7c1721c8
doc_id: 912667
cord_uid: w05d8wa7

BACKGROUND: Combination therapy with dexamethasone, remdesivir, and baricitinib has become a promising treatment for moderate or severe COVID-19; however, we have observed transient leukocytopenia in COVID-19 patients who received combination therapy. METHODS: Twelve consecutive COVID-19 patients treated with combination therapy were included in this retrospective analysis. Blood cell counts collected at the following three time points were analyzed: before the start of therapy (period 1), within 24 h of starting therapy (period 2), and within 48 h of period 2 (period 3). RESULTS: The leukocyte count significantly decreased in period 2 compared to period 1 and then significantly increased in period 3 without withdrawal of baricitinib. The neutrophil count transiently decreased in period 2 and recovered in period 3. CONCLUSIONS: Clinicians should be aware of transient leukocytopenia in patients with COVID-19 during the early phase of combination therapy.

In Japan, the fourth wave of COVID-19 occurred from April to June 2021. In randomized clinical trials, treatment with baricitinib plus remdesivir has been shown to reduce recovery time and improve clinical symptoms in patients with COVID-19 [1] . Baricitinib was approved by Japan's Ministry of Health, Labour, and Welfare as a therapeutic drug for COVID-19 on April 23, 2021; therefore, three drugs, namely dexamethasone, remdesivir, and baricitinib, have now been approved for treating moderate or severe cases of COVID-19 in Japan. A randomized, double-blind study has demonstrated that the additional administration of baricitinib to standard therapy (corticosteroids or corticosteroids plus remdesivir) reduces the mortality rate for COVID-19 patients who required oxygenation [2] . Besides, a recent retrospective observational study has shown that combination therapy with baricitinib, remdesivir, and dexamethasone is safe and effective in moderate-to-severe COVID-19 patients in real-world clinical practice [3] . Based on these backgrounds, the three-drug regimen is expected to become a promising treatment for moderate-to-severe COVID-19 patients. While treating COVID-19 patients with combination therapy comprising these three agents, we have observed unusual transient leukocytopenia in the early phase of the combination therapy.

Participants included 12 consecutive patients diagnosed with COVID-19 based on polymerase chain reaction testing of a nasopharyngeal swab, who received combination therapy with corticosteroid, remdesivir, and baricitinib at Hamamatsu University Hospital between May 5 and June 18, 2021. Blood cell counts including total and differential leukocyte count, hemoglobin concentration, and platelet count were retrospectively analyzed from samples collected at the following three time points: before the start of combination therapy (period 1), within 24 h of starting combination therapy (period 2), and within 48 h of period 2 (period 3). The data are expressed as the median with interquartile range (IQR). Statistical analyses were performed using GraphPad Prism Version 8 (GraphPad Software, San Diego, CA, USA). The ManneWhitney U test was used for the analysis of continuous variables. Results with a pvalue < 0.05 were considered to be statistically significant.

The clinical characteristics of the enrolled patients are shown in Table 1 . The median patient age was 56 years, and five patients (41.7%) were female. The median duration from onset to admission was 9 days. Eight cases required standard oxygen therapy from a nasal cannula, two required oxygen therapy from a high-flow nasal cannula, and one required mechanical ventilation support. Nine of the 12 patients had underlying diseases including respiratory disorders. All patients received systemic corticosteroids, remdesivir, and baricitinib soon after admission. The blood cell counts of each individual case are summarized in Table 2 . The leukocyte count on admission (period 1) of all patients was within the normal range. As shown in Fig. 1A , the leukocyte count significantly decreased at period 2 with combination therapy compared to period 1 (median, 4915/mL; IQR, 4302.5e5910 vs. median, 2580/mL; IQR, 2355e3107.5, p ¼ 0.0006), and subsequently increased at period 3 (median, 7205/mL; IQR, 5972.5e8605, p ¼ 0.0001; Fig. 1A ). There was no significant change in hemoglobin concentration or platelet count from period 1 to period 3 ( Fig. 1B and C) . We also analyzed changes in neutrophil and lymphocyte counts in the nine patients whose leukocyte fractions could be evaluated. As shown in Table 1 Fig. 2A , the neutrophil count was significantly decreased at period 2 compared to period 1 (median, 4669/mL; IQR, 4039e5024, vs. median, 1631/mL; IQR, 1264e2161, p ¼ 0.019), and significantly increased at period 3 (median, 5453/mL; IQR, 4383.5e6642.5, p ¼ 0.018; Fig. 2A ); however, no significant change was observed in lymphocyte count from period 1 to period 3 (Fig. 2B ).

This study provides the first evidence that combination therapy for COVID-19 with dexamethasone, remdesivir, and baricitinib induces transient leukocytopenia, which is mainly due to transient reduction of neutrophils. The mechanism of transient leukocytopenia soon after combination therapy is unknown; however, considering that leukocytopenia occurred in a very short period, the temporally abnormal distribution of leukocytes may be a potential cause. Indeed, inhibition of signal transducer and activator of transcription 3 (STAT3) phosphorylation reduces intracellular adhesion molecule 1 (ICAM1) expression [4] , which may inhibit the adhesion of neutrophils to blood vessel walls and facilitate extravascular migration. Given that baricitinib is a reversible inhibitor of Janus kinase (JAK) 1/JAK2, which suppresses cytokine-induced phosphorylation of STAT3, baricitinib potentially induces short-term leukocyte depletion in blood, and thus, transient leukocytopenia.

Clinicians should be aware that transient leukocytopenia occurs in the early phase of combination therapy with dexamethasone, remdesivir, and baricitinib for COVID-19. According to the drug information for baricitinib [5, 6] , persistent leukocytopenia is a criterion for the withdrawal of baricitinib; however, leukocytopenia is transient during combination therapy, and the leukocyte count recovered to the normal range without withdrawal of baricitinib. The underlying mechanisms of transient leukocytopenia during combination therapy are not fully understood and should be elucidated in future studies.

This study is subject to several limitations. First, the number of enrolled cases was small. Nevertheless, we believe that transient leukocytopenia in 11 of 12 cases ( Table 2 ) was unlikely to be a coincidence. Second, the cause of transient leukocytopenia could not be precisely determined in this study. Since changes in leukocyte count occurred during the combination therapy, drug-induced effects may have resulted in the leukocytopenia. Considering the mechanism of action of baricitinib [7] , it is a potential candidate for inducing transient leukocytopenia. Interactions between baricitinib and remdesivir may have affected transient leukocytopenia.

Further studies with larger numbers of patients are required to address these issues. 

Baricitinib plus remdesivir for hospitalized adults with covid-19

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19

Suppressing STAT3 activity protects the endothelial barrier from VEGF-mediated vascular permeability

Highlights of prescribing information

Up to date

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib

Box-and-whiskers plots reveal the neutrophil count (A) and lymphocyte count (B) at each period. Period 1 was defined as the start of combination therapy. Period 2 was defined as within 24 h of starting combination therapy. Period 3 was defined as within 48 h of period 2. The number of cases at each time point is as follows: Period 1 (n ¼ 5)

Clinicians should be aware of transient leukocytopenia occurring in the early phase of combination therapy with dexamethasone, remdesivir, and baricitinib in COVID-19 patients.

The authors have no conflicts of interest to declare in relation to this work. r e f e r e n c e s